Masofaniten
Clinical data | |
---|---|
Other names | EPI-7386 |
Routes of administration | By mouth |
Drug class | N-Terminal domain antiandrogen |
Identifiers | |
| |
JSmol) | |
| |
|
Masofaniten, also known by its developmental code name EPI-7386, is an
IC50hepatocytes.[1][2][3] It was planned to enter phase I clinical trials in 2020.[3] Preliminary results of a phase I/II clinical trial were published in 2023.[4][5]
= 535 nM vs. 9,580 nM, respectively), as well as greater stability in human